Schonfeld Strategic Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.6M | Sell |
567,175
-257,243
| -31% | -$9.35M | 0.14% | 134 |
|
|
2025
Q1 | $29.9M | Buy |
824,418
+76,989
| +10% | +$2.79M | 0.18% | 73 |
|
|
2024
Q4 | $31.4M | Buy |
747,429
+346,596
| +86% | +$14.6M | 0.18% | 69 |
|
|
2024
Q3 | $22.3M | Sell |
400,833
-316,114
| -44% | -$17.6M | 0.15% | 94 |
|
|
2024
Q2 | $29.5M | Buy |
716,947
+276,149
| +63% | +$11.3M | 0.19% | 85 |
|
|
2024
Q1 | $20.6M | Buy |
440,798
+97,986
| +29% | +$4.57M | 0.14% | 144 |
|
|
2023
Q4 | $16.4M | Buy |
+342,812
| New | +$16.4M | 0.11% | 187 |
|
|
2023
Q2 | – | Sell |
-19,474
| Closed | -$781K | – | 2264 |
|
|
2023
Q1 | $781K | Buy |
+19,474
| New | +$781K | 0.01% | 1018 |
|
|
2022
Q3 | – | Sell |
-21,348
| Closed | -$1.27M | – | 3025 |
|
|
2022
Q2 | $1.27M | Buy |
+21,348
| New | +$1.27M | 0.01% | 847 |
|
|
2021
Q4 | – | Sell |
-9,670
| Closed | -$872K | – | 2274 |
|
|
2021
Q3 | $872K | Buy |
9,670
+7,353
| +317% | +$663K | 0.01% | 939 |
|
|
2021
Q2 | $221K | Buy |
+2,317
| New | +$221K | ﹤0.01% | 1578 |
|
|
2020
Q1 | – | Sell |
-6,545
| Closed | -$279K | – | 1441 |
|
|
2019
Q4 | $279K | Buy |
+6,545
| New | +$279K | 0.01% | 1012 |
|
|
2019
Q3 | – | Sell |
-13,900
| Closed | -$883K | – | 1185 |
|
|
2019
Q2 | $883K | Sell |
13,900
-3,800
| -21% | -$241K | 0.03% | 482 |
|
|
2019
Q1 | $1.23M | Sell |
17,700
-15,907
| -47% | -$1.1M | 0.04% | 452 |
|
|
2018
Q4 | $1.46M | Sell |
33,607
-2,593
| -7% | -$113K | 0.06% | 382 |
|
|
2018
Q3 | $2.76M | Buy |
+36,200
| New | +$2.76M | 0.12% | 227 |
|
|
2018
Q2 | – | Sell |
-40,050
| Closed | -$2.04M | – | 916 |
|
|
2018
Q1 | $2.04M | Buy |
+40,050
| New | +$2.04M | 0.15% | 197 |
|
|
2017
Q2 | – | Sell |
-4,337
| Closed | -$295K | – | 727 |
|
|
2017
Q1 | $295K | Buy |
+4,337
| New | +$295K | 0.03% | 474 |
|